Kobe University researchers reported off-the-shelf iPSC-derived allogeneic gamma delta (γδ) T cells that suppressed colorectal cancer growth in mouse xenograft models, pointing to a more scalable alternative to autologous approaches. In Stem Cell Reports, the team led by Takashi Aoi described mass-producible γδ T cells with an approximately 80,000-fold multiplication and the ability to attack patient-derived colorectal cancer tissues implanted into mice. The researchers emphasized that current solid-tumor performance limitations and time/cost constraints of autologous CAR-T motivate allogeneic development paths. The work adds to preclinical momentum for universal T-cell platforms targeting solid tumors and may influence how sponsors design next steps for manufacturing efficiency and safety screening.